{"name":"Fundacion IDEAA","slug":"fundacion-ideaa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Emtricitabine / Tenofovir Disoproxil Pill","genericName":"Emtricitabine / Tenofovir Disoproxil Pill","slug":"emtricitabine-tenofovir-disoproxil-pill","indication":"HIV-1 infection treatment (as part of combination antiretroviral therapy)","status":"marketed"}]}],"pipeline":[{"name":"Emtricitabine / Tenofovir Disoproxil Pill","genericName":"Emtricitabine / Tenofovir Disoproxil Pill","slug":"emtricitabine-tenofovir-disoproxil-pill","phase":"marketed","mechanism":"Emtricitabine and tenofovir disoproxil are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.","indications":["HIV-1 infection treatment (as part of combination antiretroviral therapy)","HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOTGVLX2J3N1ctTDc4bkViNmVSZHlLMUpVSGo5TE8tMGQzYlpVT0VYQUtMMVFlXzN0WEwwX3NDTG1xOW8tNnd0WmM1Skx6SjRKSkl5MjFPWlM2NlpkcVByVmFDVWxMZlJzVmdZRnYtUDJabUNNbWJSVmxNbGxPNVBGcnMtaG5RalQwSWpreFJpOWFmX0w2bVpwRmxmRUJLOTQ?oc=5","date":"2025-07-02","type":"pipeline","source":"newsismybusiness.com","summary":"De la Cruz Ogilvy marks 40 years with Cannes Lions 2025 Festival win - newsismybusiness.com","headline":"De la Cruz Ogilvy marks 40 years with Cannes Lions 2025 Festival win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQbDZFSzhVcVp1MTlzTTB1UmNFRWFfU1dUUjdRMWNsTEs4NThELVNrdjFsSWl4a08tR1Z3YmZ2X2xWallKdW01cEZUQlhzVnlfNEJLZlNxM1N6ekN6SmVOOEpIVkFoVXplNlhMNGcxbk9xZ3VnTldpQjlzNnN1Z19kb3kzLTNpTFpkQlV6a2hOTkFOQnl3VmtNMEZVY3lWdw?oc=5","date":"2020-12-09","type":"pipeline","source":"Gates Foundation","summary":"Why we're giving $250 million more to fight COVID-19 - Gates Foundation","headline":"Why we're giving $250 million more to fight COVID-19","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}